Clinical trial NCT03994406: Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
Official title: A Controlled Phase 2 Study for Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Contact Lens Discomfort
Contact Lens-induced Corneal Disorder
Contact Lens Acute Red Eye
Contact Lens-induced Corneal Fluorescein Staining
Keywords: contact lens
ocular erythema
contact lens discomfort
Lead sponsor: Glia, LLC
Sponsor class: INDUSTRY
First posted: 2019-06-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1:1, study drug:placebo; block design.
Primary purpose: TREATMENT

Brief summary: This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.

Detailed description: The clinical hypothesis is that CLM2 topical gel applied dermally on the forehead twice daily will be more effective than placebo (a) in reducing or eliminating ocular discomfort associated with contact lens wear, (b) prolong hours of comfortable wear, (c) prolong total hours of contact lens wear, (d) improve ease of insertion and removal of contact lens, and ( c) reduces friction between cornea/lens and lens/eyelid, without use of artificial eye drops or gels. One mechanism supporting this hypothesis is preliminary evidence of increased meibum secretion following CLM2 topical gel application.

Eligibility criteria: Inclusion Criteria:

1. Male or female of any race ≥18 years of age at Visit 1 Screening.
2. Has provided verbal and written informed consent.
3. Be able and willing to follow instructions, including participation in all study assessments and visits.
4. Has been wearing soft contact lens in both eyes at least 2 days per week for at least a month.
5. Duration of comfortable lens wear daily is less than desired.
6. Suffers from at least two other symptoms while wearing lens with contact lens discomfort of grade 2 or higher:

   1. Dryness.
   2. Grittiness
   3. Blurred vision
   4. Itching
   5. Conjunctival redness
   6. Burning
   7. Stinging.
   8. Lens awareness
   9. Use of artificial tears or gels two or more times a day during contact lens wear hours.
7. Berkeley Dry Eye Flow Chart (DEFC) score ≥3.

Exclusion Criteria:

1. BCVA at baseline \<20/40.
2. Wearing contact lens only in one eye.
3. Wearers of the following contact lenses: Extended wear, prosthetic, scleral, and intracorneal gas permeable.
4. Pregnant women or women of childbearing potential who are not using contraception.
5. Diagnosis of the following autoimmune diseases: Addison's disease, Grave's disease, Hashimoto's thyroiditis, lupus, and Sjogren's syndrome.
6. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such dystrophies, infections, etc.
7. Has a condition or be in a situation that, the opinion of the investigator, that may interfere significantly with the subject's participation in the study. No active ocular condition or disease.
8. Has a known adverse reaction and/or sensitivity to either study drug or its components.
9. Unwilling to remove contact lens overnight.
10. Unwilling to attempt to wear contact lens seven (7) days a week during the study period.
11. Plan to change brand of contact lens during study period.
12. Unwilling to wear contact lens for at least 10 hours if comfort permits, or until discomfort requires removal of contact lens prior to 10 hours.
13. Unwilling to discontinue swimming with immersed head for the duration of the study.
14. Unwilling to withhold the use of artificial tears, gels, or wetting agents during periods when contact lens is worn during the study period.
15. Cannot withhold the following medications during the study period:

    antihistamines, some diuretics, antidepressants, antipsychotics, Restasis, Xiidra, Accutane, glaucoma medications, other anti-cholinergics; as well as gabapentin.
16. Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.

Primary outcomes:
measure: Hours of continuous comfortable contact lens wear
timeFrame: 21 days
measure: Contact Lens Questionnaire-8 (CLDEQ-8)
timeFrame: 21 days
measure: Berkeley Dry Eye Flow Chart
timeFrame: 21 days
measure: Fluorescein corneal staining
timeFrame: 21 days
Secondary outcomes:
measure: Eye discomfort from CLDEQ-8, frequency
timeFrame: 21 days
measure: Eye discomfort from CLDEQ-8, intensity
timeFrame: 21 days
measure: Glia contact lens symptoms questionnaire
timeFrame: 21 days
measure: Fluorescein conjunctival staining
timeFrame: 21 days
measure: Tear film examination by TearScan
timeFrame: 60-80 minutes
measure: Tear film examination by TearScan
timeFrame: 21 days
measure: Tear film breakup time
timeFrame: 60-80 minutes
measure: Tear film breakup time
timeFrame: 21 days
measure: Tear meniscus height
timeFrame: 60-80 minutes
measure: Tear meniscus height
timeFrame: 21 days
measure: Visual acuity
timeFrame: 21 days
measure: Tear osmolarity
timeFrame: 21 days
measure: Schirmer test
timeFrame: 21 days
Other outcomes:
Locations:
city: Berkeley
country: United States
facility: UC Berkeley Clinical Research Center
state: California
Study officials:
affiliation: University of California, Berkeley
name: Meng C. Lin, OD,PhD,FAAO
role: PRINCIPAL_INVESTIGATOR
References: